Ovarian carcinoma 

• First-line therapy in combination with a platinum compound for the treatment of advanced metastatic carcinoma of the ovary. 
• Second-line therapy for the treatment of advanced metastatic carcinoma of the ovary.

Breast carcinoma 

• Adjuvant treatment of node-positive breast cancer administered sequentially to standard combination therapy. 
• Therapy after relapse within 6 months of adjuvant therapy. Prior therapy should have included an anthracycline unless clinically contraindicated. 
• Second-line therapy after failure of combination chemotherapy for metastatic disease. Prior therapy should have included an anthracycline unless clinically contraindicated. 
• For the treatment of advanced or metastatic breast cancer in combination with trastuzumab in patients who over express HER-2 at 3+ level as determined by immunohistochemistry or FISH +.

Non-small cell lung carcinoma (NSCLC) 

First-line therapy in combination with a platinum compound for the treatment of non-small cell carcinoma of the lung in patients who are not candidates for potentially curative surgery and / or radiation therapy.

Kaposi’s sarcoma 

Second-line treatment of AIDS-related Kaposi’s sarcoma

Compositions :

Each mL contain Paclitaxel 6 mg

Storage Condition : 

Store below 30°C

Shelf Life :